CA2284170C - Identification of agents for use in the treatment of alzheimer's disease - Google Patents
Identification of agents for use in the treatment of alzheimer's disease Download PDFInfo
- Publication number
- CA2284170C CA2284170C CA002284170A CA2284170A CA2284170C CA 2284170 C CA2284170 C CA 2284170C CA 002284170 A CA002284170 A CA 002284170A CA 2284170 A CA2284170 A CA 2284170A CA 2284170 C CA2284170 C CA 2284170C
- Authority
- CA
- Canada
- Prior art keywords
- sample
- metal
- sds
- chelator
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Analytical Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US81612297A | 1997-03-11 | 1997-03-11 | |
| US08/816,122 | 1997-03-11 | ||
| PCT/US1998/004683 WO1998040071A1 (en) | 1997-03-11 | 1998-03-11 | Identification of agents for use in the treatment of alzheimer's disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2284170A1 CA2284170A1 (en) | 1998-09-17 |
| CA2284170C true CA2284170C (en) | 2008-12-02 |
Family
ID=25219748
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002284170A Expired - Fee Related CA2284170C (en) | 1997-03-11 | 1998-03-11 | Identification of agents for use in the treatment of alzheimer's disease |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1007048A4 (de) |
| JP (1) | JP2001514661A (de) |
| AU (1) | AU748768B2 (de) |
| CA (1) | CA2284170C (de) |
| WO (1) | WO1998040071A1 (de) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6743771B2 (en) * | 1995-12-29 | 2004-06-01 | Novactyl, Inc. | Methods and compositions for controlling protein assembly or aggregation |
| US7045531B1 (en) | 1997-03-11 | 2006-05-16 | The General Hospital Corporation | Composition comprising a metal chelator and a method of treating amyloidosis by administering the metal chelator |
| WO1999009981A1 (en) | 1997-08-21 | 1999-03-04 | P.N. Gerolymatos S.A. | Use of phanquinone for the treatment of alzheimer's disease |
| JP2001519529A (ja) | 1997-10-06 | 2001-10-23 | ザ ジェネラル ホスピタル コーポレイション | 遅発性ジスキネジーを予測するために薬物をスクリーニングするための方法 |
| US6323218B1 (en) * | 1998-03-11 | 2001-11-27 | The General Hospital Corporation | Agents for use in the treatment of Alzheimer's disease |
| US6638711B1 (en) | 1999-04-29 | 2003-10-28 | The General Hospital Corporation | Methods for identifying an agent that inhibits oxygen-dependent hydrogen peroxide formation activity but does not inhibit superoxide-dependent hydrogen peroxide formation |
| EP1115389B1 (de) | 1998-09-25 | 2014-03-12 | PhilERA New Zealand Limited | Antagonisten und agonisten der fructosamin oxidase |
| DK1140090T3 (da) | 1999-01-07 | 2005-04-18 | Gerolymatos P N Sa | Anvendelse af phanquinon til behandlingen eller hindringen af hukommelsessvigt |
| DE19909357A1 (de) * | 1999-03-03 | 2000-09-07 | Gerd Multhaup | Kupferagonist, der an die Kupferbindungsstelle von APP bindet und/oder eine hemmende Wirkung auf die Freisetzung des Amyloid-Aß-Peptids ausübt |
| DE60043165D1 (de) * | 1999-08-04 | 2009-11-26 | Univ Southern California | Globularer Aufbau vom Amyloid-beta- protein und deren Verwendungen |
| US7632803B2 (en) | 1999-10-01 | 2009-12-15 | Dmi Life Sciences, Inc. | Metal-binding compounds and uses therefor |
| US7592304B2 (en) | 1999-10-01 | 2009-09-22 | Dmi Life Sciences, Inc. | Metal-binding compounds and uses therefor |
| AU2001239544A1 (en) * | 2000-03-22 | 2001-10-03 | Bf Research Institute, Inc. | Image diagnosis probe based on substituted azobenzene or analogue thereof for disease attributable to amyloid accumulation and composition for image diagnosis containing the same |
| AUPR976401A0 (en) * | 2001-12-27 | 2002-01-31 | Alzhyme Pty Ltd | Agents for the treatment of alzheimer's disease and screening methods for the same |
| AU2002351880B2 (en) * | 2001-12-27 | 2007-08-30 | Neuroscientific Biopharmaceuticals Pty Ltd | Screening methods and the use of agents identified using the same |
| CN1649577A (zh) | 2002-03-08 | 2005-08-03 | 普罗特米克斯公司 | 预防和/或治疗心血管疾病和/或相关的心衰 |
| CA2875522A1 (en) | 2002-08-20 | 2004-03-04 | Philera New Zealand Limited | Dosage forms and related therapies |
| US20070185072A1 (en) * | 2003-03-21 | 2007-08-09 | Christophe Boldron | Nitrogeneous polycyclic derivatives useful as chelators of metal ions and their applications |
| CN1849112B (zh) * | 2003-09-09 | 2012-06-13 | 吉里德科学公司 | 治疗性脂质体 |
| EP1694317A4 (de) * | 2003-12-19 | 2010-05-12 | Protemix Corp Ltd | Kupfer-antagonisten-verbindungen |
| PT1778618E (pt) | 2004-07-19 | 2014-03-04 | Philera New Zealand Ltd | Síntese de trietilenotetraminas |
| GEP20105110B (en) | 2004-08-03 | 2010-11-10 | Transtech Pharma Inc | Rage fusion proteins and their use |
| SG171670A1 (en) | 2006-05-05 | 2011-06-29 | Transtech Pharma Inc | Rage fusion proteins, formulations, and methods of use thereof |
| US8338089B2 (en) | 2006-11-20 | 2012-12-25 | The Johns Hopkins University | Method of inhibiting lentiviral infectivity utilizing zinc chelation to inhibit Vif activity |
| KR101595634B1 (ko) | 2007-06-14 | 2016-02-18 | 갈락티카 파마슈티칼스, 인크. | Rage 융합 단백질 |
| WO2009108999A1 (en) * | 2008-03-03 | 2009-09-11 | Ross Stewart Grant | Pharmaceutical formulations of resveratrol and methods of use thereof for treating cell disorders |
| AU2010240569A1 (en) | 2009-04-20 | 2011-10-20 | Pfizer Inc. | Control of protein glycosylation and compositions and methods relating thereto |
| WO2018236221A2 (en) * | 2017-06-03 | 2018-12-27 | Can Holding B.V. | Neurodegenerative peptide deposit dissolution |
| KR102048846B1 (ko) * | 2017-11-20 | 2019-11-27 | 한국생명공학연구원 | 혈관 질환 치료제 및 이의 스크리닝 방법 |
| US12521362B2 (en) * | 2019-07-25 | 2026-01-13 | Tokyo University Of Science Foundation | Agent for treating, preventing, or improving psychiatric and nervous system disorders or symptoms |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5434050A (en) * | 1991-08-13 | 1995-07-18 | Regents Of The University Of Minnesota | Labelled β-amyloid peptide and methods of screening for Alzheimer's disease |
| JP3277211B2 (ja) * | 1991-11-12 | 2002-04-22 | プラナ・バイオテクノロジー・リミテッド | アルツハイマー病の試験方法と治療方法 |
| US5688516A (en) * | 1992-11-12 | 1997-11-18 | Board Of Regents, The University Of Texas System | Non-glycopeptide antimicrobial agents in combination with an anticoagulant, an antithrombotic or a chelating agent, and their uses in, for example, the preparation of medical devices |
| JPH07149668A (ja) * | 1993-11-30 | 1995-06-13 | Kanegafuchi Chem Ind Co Ltd | アミロイド沈着検出用物質 |
| US5688651A (en) * | 1994-12-16 | 1997-11-18 | Ramot University Authority For Applied Research And Development Ltd. | Prevention of protein aggregation |
| US5854204A (en) * | 1995-03-14 | 1998-12-29 | Praecis Pharmaceuticals, Inc. | Aβ peptides that modulate β-amyloid aggregation |
| US6043224A (en) * | 1996-09-05 | 2000-03-28 | The Massachusetts Institute Of Technology | Compositions and methods for treatment of neurological disorders and neurodegenerative diseases |
-
1998
- 1998-03-11 JP JP53971898A patent/JP2001514661A/ja not_active Ceased
- 1998-03-11 EP EP98911551A patent/EP1007048A4/de not_active Withdrawn
- 1998-03-11 CA CA002284170A patent/CA2284170C/en not_active Expired - Fee Related
- 1998-03-11 AU AU65484/98A patent/AU748768B2/en not_active Ceased
- 1998-03-11 WO PCT/US1998/004683 patent/WO1998040071A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| CA2284170A1 (en) | 1998-09-17 |
| WO1998040071A1 (en) | 1998-09-17 |
| EP1007048A4 (de) | 2004-09-22 |
| EP1007048A1 (de) | 2000-06-14 |
| AU6548498A (en) | 1998-09-29 |
| AU748768B2 (en) | 2002-06-13 |
| JP2001514661A (ja) | 2001-09-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2284170C (en) | Identification of agents for use in the treatment of alzheimer's disease | |
| US6323218B1 (en) | Agents for use in the treatment of Alzheimer's disease | |
| WO1998040071A9 (en) | Identification of agents for use in the treatment of alzheimer's disease | |
| McLachlan | Aluminium and the risk for Alzheimer's disease | |
| Atwood et al. | Characterization of copper interactions with Alzheimer amyloid β peptides: identification of an attomolar‐affinity copper binding site on amyloid β1‐42 | |
| PL188838B1 (pl) | Zastosowanie kliochinolu do wytwarzania środka farmaceutycznego i środek farmaceutyczny | |
| US7045531B1 (en) | Composition comprising a metal chelator and a method of treating amyloidosis by administering the metal chelator | |
| US20050112543A1 (en) | Method of screening for drugs useful in treating Alzheimer's disease | |
| US6638711B1 (en) | Methods for identifying an agent that inhibits oxygen-dependent hydrogen peroxide formation activity but does not inhibit superoxide-dependent hydrogen peroxide formation | |
| CA2379858C (en) | Beta-amyloid peptide inhibitors | |
| HK1033907B (en) | Metal chelators for use in the treatment of alzheimer's disease | |
| CA2601285A1 (en) | Agents for use in the treatment of amyloidosis | |
| Huckle | PBT-1 Prana biotechnology | |
| Curtain et al. | Aβ Metallobiology and the Development of Novel Metal-Protein Attenuating Compounds (MPACs) for Alzheimer's Disease | |
| JP2004506915A (ja) | 白内障を阻害又は促進する物質を同定する方法及びその使用 | |
| Okafor et al. | Next-generation Cu (II) selective peptide shuttles prevent Cu (Aβ)-induced toxicity and microglial activation in organotypic hippocampal slices | |
| Khan | Aluminium, iron, zinc and copper influence the in vitro formation of amyloid fibrils of Aβ42 in a manner which may have consequences for metal chelation therapy in Alzheimer's disease | |
| AU780380B2 (en) | Beta-amyloid peptide inhibitors | |
| White et al. | The Metallobiology of Alzheimer's Disease: From Bench to Clinic. | |
| Summers | 8-Hydroxyquinoline Copper Complexes in the Treatment of Neurodegenerative Disease | |
| Guzmán | Oxidative stress and the amyloid beta peptide in Alzheimer's disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |